About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Liver Disease Clinical Trials | 200 Studies Recruiting

Clinical TrialsLiver Disease

Liver Disease Clinical Trials

Browse 200 clinical trials for liver disease. Find studies that match your criteria and connect with research centers.

Find trials near:

New York Los Angeles Chicago Houston Phoenix Philadelphia

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 181-200 of 200 trials

CompletedEfficacy and Safety of Oltipraz in the Patients With Non-alcoholic Fatty Liver DiseaseDithiolethiones, a novel class of adenosine monophosphate-activated protein kinase (AMPK) activators, prevent insulin resistance through AMPK-dependent p70 ribosomal S6 kinase-1…NCT01373554·Dahwa-dong, Ilsanseo-gu, Goyang-si, Gyeonggi-do and 4 others CompletedRepeatability and Reproducibility of Multiparametric MRIThis study aims to prospectively assess the repeatability and reproducibility of iron-corrected T1 (cT1), T2\*, and hepatic proton density fat fraction (PDFF) quantification with…NCT03743272·Leiden and 3 others RecruitingA Community-based Prospective Cohort Study on Metabolic Dysfunction-Associated Fatty Liver Disease in Older Adults: From Metabolic Trajectories to Extrahepatic OutcomesTo establish a cohort of elderly fatty liver disease based on the community medical examination population.NCT07241195·Hangzhou, Zhejiang

Related Searches

cirrhosistrials nafldtrials

Data from ClinicalTrials.govTerms

RecruitingEstablishment of NAFLD Cohort and Development of Fibrosis MarkersThis study is designed for establishment of non-alcoholic fatty liver disease patients cohort to development of markers to predict histologic progression of liver fibrosis.NCT02206841·Seoul

RecruitingLiver-gut Axis Study Through Identification of Liver Disease-specific MicrobiomeIn this study, we aim to identify gut microbiomes specific to patients with chronic refractory liver disease and to conduct a gut-liver axis study on the pathogenesis and disease…NCT06519162·Daejeon, Jung-gu

CompletedAnti-Fibrotic Effects of Losartan In Nash Evaluation StudyThis is a randomized, controlled trial to determine whether Losartan is effective at slowing down, halting or reversing liver fibrosis in patients with non-alcoholic…NCT01051219·Plymouth, Devon and 9 others

CompletedCorrelation Between Hepatic Fibrosis and Cardiovascular Risk Evaluated by Non-invasive Tests in Patients With NAFLDThis study aims to examine the link between Non-Alcoholic Fatty Liver Disease (NAFLD) and cardiovascular diseases by studying the association between liver fibrosis degree and…NCT04774302·Marseille and 1 other

CompletedNon Invasive Assessment of Liver Fibrosis in Fatty Liver DiseaseThe purpose of this randomized clinical trial is to evaluate the utility of noninvasive markers for the detection of advanced fibrosis in patients newly diagnosed with…NCT01874249·Mexico City, Mexico City

TerminatedTherapeutic Exploratory Phase 2 Study to Evaluate the Safety and Efficacy of MB12066 in Patients With Nonalcoholic Fatty Liver Disease(NAFLD) Except CirrhosisThis is a controlled study to determine the effectiveness and safety of MB12066 in the treatment of adult patients with Nonalcoholic Fatty Liver Disease(NAFLD) except cirrhosis.NCT02029586·Seoul, Banpo-daero Seocho-gu and 9 others

CompletedClinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic FactorsNonalcoholic fatty liver disease (NAFLD) is the most common liver disease globally, with an estimated prevalence of approximately 15 to 30%.NCT06244550·Taipei

Active not recruitingPrevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 DiabetesThe aim of this study is to assess the prevalence of nonalcoholic fatty liver disease (NAFLD) in patients with type 1 diabetes receiving care at Joslin clinic using noninvasive…NCT04595474·Boston, Massachusetts

RecruitingBiomarkers in the Diagnosis and Prognosis of NAFLDFibrosis is considered the leading cause of liver diseases and related mortality.NCT06098417·Trieste

UnknownMechanism of Serum PRL in the Development of MAFLDMetabolic associated fatty liver disease (MAFLD) has currently reached a worldwide epidemic.NCT05525884·Shanghai, Shanghai Municipality

CompletedA First in Human Study to Evaluate the Safety, Tolerability and PK of GB1211 in Healthy SubjectsThis was a Phase 1, randomized, double-blind, placebo-controlled, first-in-human study in which the safety, tolerability, and pharmacokinetics of orally administered GB1211 will…NCT03809052·Leeds

Active not recruitingA Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)Researchers are looking for ways to treat a type of liver disease caused by elevated liver fat, called metabolic dysfunction-associated steatohepatitis (MASH).NCT06465186·Chandler, Arizona and 67 others

CompletedDevelopment of a Breath Test for Monitoring Patients With Liver DiseaseThe purpose of this study is to determine the safety and efficacy of the Oridion Breath ID machine in monitoring liver metabolic functions.NCT00244569·Richmond, Virginia

UnknownEmricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH CirrhosisThis is a multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of emricasan in improving event-free survival based on a composite…NCT03205345·Chandler, Arizona and 75 others

UnknownAn Observational Cohort Study Evaluating Fatty Liver Disease and Liver Fibrosis in Moderate to Severe Psoriasis• Main objectives and outcome measures. 1.NCT02174367·London

CompletedStudy in Healthy Adults Evaluating PF-07202954The study is planned as a 3 part design with investigator and participant blinded (sponsor-open), placebo controlled, randomized, dose escalation in Part 1 and Part 2; and a…NCT04857437·New Haven, Connecticut

Not yet recruitingImpact of Overt and Subclinical Hypothyroidism on Liver Fibrosis in Patients With MASLDMetabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), is one of the most common chronic liver conditions…NCT07827430

PreviousPage 10 of 10